EUCTR2011-001667-44-DE进行中（未招募）不适用
An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years at the time of signing the informed consent form
- •2. Clinical Diagnosis of SSc according to ACR criteria
- •3. Progressive SSc fulfilling at least one of the following:
- •- STPR (Skin Thickness Progression Rate) = 40, calculated as the mRSS at screening divided by time (in years) since the start of skin involvement. as reported by the patient (Denton 2007).
- •- Worsening of mRSS within the last 6 months as judged by the physician together with the patient, with involvement of at least two new anatomical sites as defined in the mRSS score (e.g. upper arm and thorax) or progression by at least two points in at least two anatomical sites as defined by the mRSS
- •4. Presence of SSc skin lesions on one or both forearms
- •5. Modified Rodnan Skin score (mRSS) =16 at baseline
- •6. ANA-positive
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •1. Ongoing Severe SSc manifestations, such as pulmonary arterial hypertension (PAH) with dyspnea NYHA III or more, scleroderma renal crisis.
- •2. Vital capacity < 60% as measured within 6 months prior to the first dose of study medication
- •3. GFR < 30% of normal measured within 6 months prior to the first dose of study medication.
- •4. Treatment with Rituximab within 12 months or other biologic agent within 6 months, Mycophenolate mofetil (MMF) or Cyclophosphamide within 6 months, Methotrexate, Azathioprine or other immunosuppressants within 3 months prior to the first dose of study medication.
- •5. History of myocardial infarction or current uncontrolled angina, severe uncontrolled ventricular arrhythmias, symptomatic congestive heart failure, unstable angina pectoris, or electrocardiographic evidence of acute ischemia.
- •6. Marked baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTc interval >450 milliseconds
- •7. History of additional risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome)
- •8. Treatment with concomitant medications that prolong the QT interval.
- •9. History of, or current ischemic CNS disease.
- •10. Current malignancy. A 5-year cancer-free period is required with the exception of skin basal or squamous cell carcinoma or cervical cancer in situ that has been excised.
- •11. Current severe infection
- •12. Known positive serology for HIV or active or latent hepatitis infection.
- •13. Treatment with endothelin receptor antagonist within 6 weeks prior to the first dose of study medication
- •14. Drug abuse
- •15. Major surgery within 3 weeks prior to study entry.
- •16. Known or suspected hypersensitivity to ABR-215757 or excipients.
- •17. Female patient of child-bearing potential who is not using a medically accepted safe method of contraception. All female patients of child-bearing potential must have a negative urine pregnancy test at the Screening and Baseline Visits. As interaction studies between ABR-215757 and hormonal contraceptives have not yet been performed, women using hormonal contraceptives such as the contraceptive pill, must also use a complementary contraceptive device, i.e. barrier method, during the treatment period and for at least 1 month thereafter.
- •18. Female patient of child-bearing potential who is pregnant or lactating.
- •19. Simultaneous participation or participation within 4 months or 5 half lives (whichever is longer) prior to study entry in any other study involving investigational drugs or other experimental therapy.
- •20. Other significant, unstable medical disease not related to SSc that in the investigator’s opinion would confound the study result or put the patient at risk
- •21. Patients likely to receive oral or intravenous steroids or immunosuppressant for other non-SSc condition during the study duration, as this will confound the study result.
- •22. Vaccination within 4 weeks prior to the first dose of study medication.
研究者
相似试验
进行中（未招募）
不适用
An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod)Systemic SclerosisMedDRA version: 14.0Level: PTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 14.0Level: LLTClassification code 10036814Term: Progressive systemic sclerosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-001667-44-SEActive Biotech AB20
招募中
2 期
Effectiveness and safety of LM011 in treating subjects diagnosed with non-alcoholic steatohepatitis (NASH).on-Alcoholic Steatohepatitis (NASH)Non-Alcoholic Steatohepatitis (NASH)Metabolic and Endocrine - Metabolic disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12619000610134ifemax Laboratories (Australia) Pty Ltd20
进行中（未招募）
1 期
Open label study to assess the efficacy, safety and dosing of clevidipine in children undergoing surgery.EUCTR2013-001268-44-Outside-EU/EEAChiesi USA, Inc.80
已完成
不适用
A clinical study to test the safety and the efficacy of a single-pill combination of 2 antihypertensive and 1 lipid-lowering drug in patients already well treated with the concomitant administration of the same three drugs on separate tabletsHypertension and dyslipidemiaCirculatory SystemISRCTN27159806Institut de Recherche Internationales Servier130
进行中（未招募）
1 期
A research study on how well concizumab works for you if you have haemophilia A or B with or without inhibitors (explorer10)Haemophilia A with or without inhibitorsHaemophilia B with our without inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10053753Term: Hemophilia A without inhibitorsSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10053754Term: Hemophilia B without inhibitorsSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-000504-11-BGovo Nordisk A/S127